Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has entered into a Material Definitive Extension Agreement with an institutional investor on September 30, 2024. This agreement is an amendment to the Securities Purchase Agreement (SPA) dated July 5, 2024, and pertains to a potential financing arrangement of not less than $5 million, referred to as the Subsequent Financing. The institutional investor retains exclusive negotiation rights and a right of first refusal for any Subsequent Financing until November 30, 2024, known as the Outside Date. If the financing is not secured by this date, the investor's nominated board members will resign immediately. The company has the option to extend the Outside Date by up to 30 days, with board approval, to accommodate the re-audit of financial statements for fiscal years 2022 and 2023. The full details of the Extension Agreement have been filed with the SEC and are incorporated into the Form 8-K report.

Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has entered into a Material Definitive Extension Agreement with an institutional investor on September 30, 2024. This agreement is an amendment to the Securities Purchase Agreement (SPA) dated July 5, 2024, and pertains to a potential financing arrangement of not less than $5 million, referred to as the Subsequent Financing. The institutional investor retains exclusive negotiation rights and a right of first refusal for any Subsequent Financing until November 30, 2024, known as the Outside Date. If the financing is not secured by this date, the investor's nominated board members will resign immediately. The company has the option to extend the Outside Date by up to 30 days, with board approval, to accommodate the re-audit of financial statements for fiscal years 2022 and 2023. The full details of the Extension Agreement have been filed with the SEC and are incorporated into the Form 8-K report.